Peripheral blood and neuropsychological markers for the onset of action of antidepressant drugs in patients with Major Depressive Disorder

<p>Abstract</p> <p>Background</p> <p>In Major Depressive Disorder (MDD), treatment outcomes with currently available strategies are often disappointing. Therefore, it is sensible to develop new strategies to increase remission rates in acutely depressed patients. Many studies reported that true drug response can be observed within 14 days (early improvement) of antidepressant treatment. The identical time course of symptom amelioration after early improvement in patients treated with antidepressants of all classes or with placebo strongly suggests a common biological mechanism, which is not specific for a particular antidepressant medication. However, the biology underlying early improvement and final treatment response is not understood and there is no established biological marker as yet, which can predict treatment response for the individual patient before initiation or during the course of antidepressant treatment. Peripheral blood markers and executive functions are particularly promising candidates as markers for the onset of action and thus the prediction of final treatment outcome in MDD.</p> <p>Methods/Design</p> <p>The present paper presents the rationales, objectives and methods of a multi-centre study applying close-meshed repetitive measurements of peripheral blood and neuropsychological parameters in patients with MDD and healthy controls during a study period of eight weeks for the identification of biomarkers for the onset of antidepressants' action in patients with MDD. Peripheral blood parameters and depression severity are assessed in weekly intervals from baseline to week 8, executive performance in bi-weekly intervals. Patients are participating in a randomized controlled multi-level clinical trial, healthy controls are matched according to mean age, sex and general intelligence.</p> <p>Discussion</p> <p>This investigation will help to identify a biomarker or a set of biomarkers with decision-making quality in the treatment of MDD in order to increase the currently disappointing remission rates of antidepressant treatment.</p> <p>Trial Registration</p> <p>ClinicalTrials.gov: <a href="http://www.clinicaltrials.gov/ct2/show/NCT00974155">NCT00974155</a></p

The Association between Depressive Mood and Cognitive Performance in an Elderly General Population - The MEMO Study

The aim of this study was to analyse the influence of the severity of depressive symptoms on different domains of cognitive function in the elderly. In a population-based cross-sectional study, 385 participants aged 65-83 years were interviewed with the Center for Epidemiologic Studies Depression Scale (CES-D) and performed a standardized neuropsychological test assessing attention, memory, cognitive speed and motor function. Multivariate linear regression analyses revealed a significant effect of depressive symptoms on a single test (Stroop test 1) and two summary scores (memory and motor function). After full adjustment for education and Mini Mental State Examination, the memory score was partly attenuated. Stratified analysis showed that an increase in CES-D scores led to a larger decline of cognitive test results in participants with mild to moderate depressive symptoms, compared to those with a high degree of depressive symptoms. Our results suggest that depressive mood in older adults is primarily associated with decreased processing speed and motor functioning, but not executive control functions. According to our results depressive mood is not necessarily associated with memory deficits in older adults. Changes in depressive symptoms in milder forms of depressive mood are associated with a larger decline in cognitive function than in severer forms of depressive mood.Bernhard T. Baune, Thomas Suslow, Almut Engelien, Volker Arolt, Klaus Berge